FIELD: medicine.
SUBSTANCE: invention relates to medicine, namely phthisiology and bacteriology, and can be used to conduct tuberculostatic tests in patients with pulmonary tuberculosis for laboratory substantiation of personalized treatment. For this purpose, the patient is assessed as a delay in the growth of the mycobacterium tuberculosis strain with his blood serum collected at the peak of drug concentrations. At the stage of preparation, a medium of Middlebrook 7H9 with a growth supplement of OADC in a volume of 105 mcl in the serum control wells, 150 mcl in the serum dilutions and growth control wells, 180 mcl per well of the blank is added to the 96-well microdilution plate. Add 30 mcl of medium to the wells with the ready dilutions of serum. After inoculation of a suspension of the strain, incubation, administration of resazurin, the luminescence intensity is measured. Then build a graph based on a computer calculation of the average values of the measured intensity. Point of growth inhibition is determined at the intersection of the serum dilution curve and the straight line constructed from the average values of the 1 % growth control of the population.
EFFECT: invention allows the evaluation and correction of chemotherapy for pulmonary tuberculosis, to evaluate the anti-tuberculosis activity of new drugs.
1 cl, 4 dwg, 2 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOUND OF 8-(4-METHYL-4H-1,2,4-TRIAZOL-3-YL)-6-(METHYLSULPHONYL)-2-(5-NITRO-2-FUROYL)-2,6-DIAZASPIRO[3.4]OCTANE, HAVING ANTI-TUBERCULOSIS ACTIVITY AGAINST MULTIDRUG-RESISTANT TUBERCULOSIS AGENT, AND METHOD FOR PRODUCTION THEREOF | 2023 |
|
RU2825646C1 |
| CULTURE MEDIUM FOR DETERMINING DRUG SUSCEPTIBILITY OF M tuberculosis TO MAIN ANTI-TUBERCULOSIS DRUGS | 2010 |
|
RU2470071C2 |
| ANTITUBERCULAR AGENT BASED ON A PYRIDOXINE DERIVATIVE | 2021 |
|
RU2772219C1 |
| USE OF (5Z)-2-AMINO-5-(1-BROM-2-OXO-2-PHENYLETHYLIDENE)-4-OXO-1H-4,5-DIHYDROFURAN-3-CARBOXIC ACID ETHER AS A MEDICINAL AGENT WITH TUBERCULOSTATIC ACTIVITY | 2022 |
|
RU2799759C1 |
| (4-(3-HYDROXYPHENYL)PIPERAZINE-1-YL)(5-NITROFURAN-2-YL)METHANON, WHICH HAS ANTITUBERCULAR ACTIVITY AGAINST THE CAUSATIVE AGENT OF MULTIDRUG-RESISTANT TUBERCULOSIS, AND THE METHOD FOR ITS PREPARATION | 2021 |
|
RU2784399C1 |
| 1-[(5-NITROFURAN-2-YL)CARBONYL]-2'-PHENYL-1H,7'H-SPIRO[AZETIDINE-3,5'-FURO[3,4-D]PYRIMIDINE], HAVING ANTI-TUBERCULOSIS ACTIVITY IN WITH RESPECT TO MULTIDRUG-RESISTANT TUBERCULOSIS AGENT, AND METHOD FOR PRODUCTION THEREOF | 2023 |
|
RU2824815C1 |
| 5-METHYL-7-(3-NITRO-[1,2,4]TRIAZOL-1-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDINE, HAVING ANTI-TUBERCULOSIS ACTIVITY AGAINST THE AGENT WITH MULTIPLE DRUG RESISTANCE, AND A METHOD FOR PRODUCTION THEREOF | 2018 |
|
RU2705591C1 |
| APPLICATION OF 2-AMINO-5-BROMO-5-(1-BROM-2-OXO-2-PHENYLETHYLIDENE)-4-OXO-1Н-4,5-DIHYDROFURAN-3-CARBOXIC ACID ETHYL AS A MEDICINE WITH TUBERCULOSTATIC ACTIVITY | 2023 |
|
RU2803601C1 |
| SILVER SALTS OF 1-ARYL-4,4,4-TRIFLUOROBUTANE-1,3-DIONES, EXHIBITING TUBERCULOSTATIC ACTIVITY | 2023 |
|
RU2817114C1 |
| COMPOUND 1-[(5-NITROFURAN-2-YL)CARBONYL]-2'-CYCLOHEXYL-1H,7'H-SPIRO[AZETIDINE-3,5'-FURO[3,4-D]PYRIMIDINE], HAVING ANTI-TUBERCULOSIS ACTIVITY AGAINST MULTIDRUG-RESISTANT TUBERCULOSIS AGENT, AND METHOD FOR PRODUCTION THEREOF | 2023 |
|
RU2825647C1 |
